Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; …
Over the last 12 months, insiders at Daré Bioscience, Inc. have bought $0 and sold $0 worth of Daré Bioscience, Inc. stock.
On average, over the past 5 years, insiders at Daré Bioscience, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 454,545 shares for transaction amount of $500,000 was made by HAWLEY ROGER (director) on 2019‑04‑11.
2019-04-11 | director | 454,545 2.8482% | $1.10 | $500,000 | -22.94% | |||
2018-06-11 | director | 140,000 1.2031% | $1.45 | $203,378 | -35.81% | |||
2016-02-22 | director | 1,182 0.0043% | $2.09 | $2,468 | -32.54% | |||
2016-02-19 | director | 3,400 0.0125% | $2.08 | $7,058 | -27.67% | |||
2016-02-18 | director | 9,000 0.033% | $2.09 | $18,802 | -25.96% | |||
2016-02-17 | director | 8,920 0.0329% | $2.12 | $18,882 | -17.62% | |||
2016-02-16 | director | 9,000 0.0325% | $2.00 | $18,028 | -5.17% | |||
2016-02-12 | director | 8,622 0.0324% | $2.00 | $17,263 | +1.03% | |||
2016-02-11 | director | 8,700 0.0324% | $2.03 | $17,665 | -1.51% | |||
2016-02-10 | director | 9,000 0.0335% | $2.08 | $18,679 | -3.43% | |||
2016-02-09 | director | 9,000 0.0333% | $2.08 | $18,697 | -3.17% | |||
2016-02-08 | director | 9,000 0.0344% | $2.15 | $19,318 | -2.93% | |||
2016-02-05 | director | 9,000 0.033% | $2.29 | $20,651 | -11.79% | |||
2016-02-04 | director | 8,126 0.0294% | $2.31 | $18,761 | -13.09% | |||
2016-02-03 | director | 8,036 0.0294% | $2.27 | $18,262 | -10.57% | |||
2016-02-02 | director | 8,790 0.0331% | $2.37 | $20,818 | -11.30% | |||
2016-02-01 | director | 9,000 0.0329% | $2.37 | $21,328 | -13.50% | |||
2016-01-29 | director | 2,400 0.0088% | $2.40 | $5,772 | -14.17% | |||
2016-01-28 | director | 9,000 0.034% | $2.45 | $22,036 | -12.87% | |||
2016-01-27 | director | 9,000 0.0331% | $2.46 | $22,132 | -15.16% |
Crane Alan L | 4771739 55.8336% | $3.97 | 1 | 0 | ||
Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 3262437 38.1734% | $3.97 | 1 | 0 | |
VENROCK ASSOCIATES V LP | 10 percent owner | 3015017 35.2784% | $3.97 | 1 | 0 | |
CVF, LLC | 10 percent owner | 2592577 30.3355% | $3.97 | 2 | 0 | |
LILLY ELI & CO | 10 percent owner | 2356227 27.5699% | $3.97 | 1 | 0 |